- Home
- OCGN vs CBIO Comparison
OCGN vs CBIO Comparison
Compare OCGN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- CBIO
- Stock Information
- Founded
- OCGN 2013
- CBIO 2003
- Country
- OCGN United States
- CBIO United States
- Employees
- OCGN N/A
- CBIO N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- CBIO
- Sector
- OCGN Health Care
- CBIO
- Exchange
- OCGN Nasdaq
- CBIO Nasdaq
- Market Cap
- OCGN 283.3M
- CBIO 308.0M
- IPO Year
- OCGN N/A
- CBIO N/A
- Fundamental
- Price
- OCGN $1.03
- CBIO $14.24
- Analyst Decision
- OCGN Strong Buy
- CBIO Strong Buy
- Analyst Count
- OCGN 3
- CBIO 5
- Target Price
- OCGN $6.00
- CBIO $25.60
- AVG Volume (30 Days)
- OCGN 1.8M
- CBIO 98.4K
- Earning Date
- OCGN 08-01-2025
- CBIO 07-31-2025
- Dividend Yield
- OCGN N/A
- CBIO N/A
- EPS Growth
- OCGN N/A
- CBIO N/A
- EPS
- OCGN N/A
- CBIO N/A
- Revenue
- OCGN $4,754,000.00
- CBIO N/A
- Revenue This Year
- OCGN N/A
- CBIO N/A
- Revenue Next Year
- OCGN N/A
- CBIO N/A
- P/E Ratio
- OCGN N/A
- CBIO N/A
- Revenue Growth
- OCGN N/A
- CBIO N/A
- 52 Week Low
- OCGN $0.52
- CBIO $10.83
- 52 Week High
- OCGN $1.29
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- OCGN 50.51
- CBIO 53.93
- Support Level
- OCGN $1.00
- CBIO $12.96
- Resistance Level
- OCGN $1.05
- CBIO $14.74
- Average True Range (ATR)
- OCGN 0.04
- CBIO 0.89
- MACD
- OCGN 0.00
- CBIO 0.02
- Stochastic Oscillator
- OCGN 55.56
- CBIO 42.11
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.